Sol-Gel Technologies Retained Earnings (Accumulated Deficit) 2016-2024 | SLGL
Sol-Gel Technologies retained earnings (accumulated deficit) from 2016 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Sol-Gel Technologies Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-220 |
| 2022 |
$-193 |
| 2021 |
$-178 |
| 2020 |
$-181 |
| 2019 |
$-152 |
| 2018 |
$-127 |
| 2017 |
$-95 |
| 2016 |
$-64 |
| 2015 |
$-43 |
Sol-Gel Technologies Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$-225 |
| 2024-03-31 |
$-227 |
| 2023-12-31 |
$-220 |
| 2023-09-30 |
$-215 |
| 2023-06-30 |
$-210 |
| 2023-03-31 |
$-203 |
| 2022-12-31 |
$-193 |
| 2022-09-30 |
$-187 |
| 2022-06-30 |
$-184 |
| 2022-03-31 |
$-184 |
| 2021-12-31 |
$-178 |
| 2021-09-30 |
$-192 |
| 2021-06-30 |
$-193 |
| 2021-03-31 |
$-185 |
| 2020-12-31 |
$-181 |
| 2020-09-30 |
$-175 |
| 2020-06-30 |
$-166 |
| 2020-03-31 |
$-159 |
| 2019-12-31 |
$-152 |
| 2019-09-30 |
$-145 |
| 2019-06-30 |
$-138 |
| 2019-03-31 |
$-133 |
| 2018-06-30 |
$-108 |
| 2018-03-31 |
$-101 |
| 2017-12-31 |
|
| 2017-09-30 |
$-90 |
| 2017-06-30 |
|
| 2016-12-31 |
$-64 |
| 2015-12-31 |
$-43 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.012B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
